Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Sep
15
Today In Oncology
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Viral Immunotherapy May Extend Survival in Advanced NSCLC After Progression on Immune Checkpoint Inhibition
Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies
ctDNA May Guide Immunotherapy in Limited-Stage SCLC
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo